The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | Updates on research into menin inhibitors for the treatment of acute leukemias
Florian Perner, MD, Hannover Medical School, Hannover, Germany, comments on the current state of research with menin inhibitors for the treatment of acute leukemias. He notes that several compounds, including ziftomenib, bleximenib, and enzomenib, are in clinical trials and show promising results. Dr Perner highlights the need for further research to determine the advantages and disadvantages of each inhibitor. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I mean this field really gets relatively while…there is a variety of other menin inhibitors now that are currently in clinical trials. Probably ziftominib, the inhibitor from Cura Oncology, is after revumenib, the one that is most advanced in the field. And I think probably in the next year or so, we are expecting potentially an approval for this drug by the FDA for NPM1 mutant leukemia...
Yeah, I mean this field really gets relatively while…there is a variety of other menin inhibitors now that are currently in clinical trials. Probably ziftominib, the inhibitor from Cura Oncology, is after revumenib, the one that is most advanced in the field. And I think probably in the next year or so, we are expecting potentially an approval for this drug by the FDA for NPM1 mutant leukemia. But also other inhibitors like bleximenib and enzomenib are compounds that are currently tested and all of them seem to be well tolerated. All of them show good signs of efficacy. So there is a lot going on in the field and we really need to see what the next months and the next years bring to see which of those inhibitors will have advantages and disadvantages over others.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
